CD8A Antibody / Tumor Infiltrating Lymphocyte Marker Antibody [clone CDLA8a-2R] (V3684)

Catalog No.	Formulation	Size
V3684-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V3684-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V3684SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V3684IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml

Recombinant RABBIT MONOCLONAL

Bulk quote request

Availability	1-3 business days
Species Reactivity	Human. Other species not known.
Format	Purified
Host	Rabbit
Clonality	Recombinant Rabbit Monoclonal
Isotype	Rabbit IgG, k
Clone Name	CDLA8a-2R
Purity	Protein A affinity chromatography
UniProt	P01732
Localization	Cell surface
Applications	Immunohistochemistry (FFPE) : 0.5-1ug/ml for 30 min at RT Prediluted IHC Only Format : incubate for 30 min at RT (1)
Limitations	This CD8A Antibody / Tumor Infiltrating Lymphocyte Marker Antibody is available for research use only.



CD8A Antibody Tonsil IHC. Immunohistochemistry analysis of CD8 alpha (CD8A) in FFPE human tonsil tissue shows strong membranous staining of numerous cytotoxic T lymphocytes within lymphoid regions, consistent with CD8-positive tumor infiltrating lymphocyte marker expression and supporting identification of dense immune cell infiltration in lymphoid tissue. Heat-induced epitope retrieval was performed in 10 mM citrate buffer, pH 6.0, for 10-20 minutes followed by cooling at room temperature.

Description

CD8 alpha (CD8A) is a transmembrane glycoprotein expressed on cytotoxic T lymphocytes and functions as a co-receptor for T cell receptor signaling through interaction with MHC class I molecules. CD8A Antibody / Tumor Infiltrating Lymphocyte Marker Antibody is widely used to evaluate immune cell infiltration within tumors, where CD8-positive T cells serve as a key indicator of anti-tumor immune activity. CD8A antibody, also referred to as CD8 alpha antibody or CD8 antigen antibody, is one of the most commonly used markers for identifying tumor infiltrating lymphocytes in cancer research.

CD8A is localized to the plasma membrane of cytotoxic T cells, making it highly suitable for tissue-based detection of immune infiltrates by immunohistochemistry and multiplex imaging approaches. As a Tumor Infiltrating Lymphocyte Marker Antibody, CD8A is used not only to detect the presence of T cells, but also to assess their distribution within tumor nests, stromal compartments, and invasive margins. These spatial patterns are often biologically significant and can reflect differences in immune accessibility, tumor evasion, and microenvironmental regulation.

CD8-positive tumor infiltrating lymphocytes are central to cancer immunology, where their abundance and localization are frequently associated with prognosis and response to therapy. CD8A antibody is therefore widely used in studies examining immune hot versus immune cold tumors, evaluating immune exclusion, and monitoring changes in T cell infiltration following therapeutic intervention. This makes CD8A Antibody / Tumor Infiltrating Lymphocyte Marker Antibody a highly relevant tool for both discovery and translational oncology research.

In immunohistochemistry workflows, CD8A staining allows visualization of cytotoxic T lymphocytes within intact tissue architecture, providing context for how immune cells interact with tumor cells. In multiplex assays, CD8A is often combined with additional markers to define immune cell subsets and functional states within the tumor microenvironment. These approaches rely on clear and specific CD8A detection to accurately interpret immune infiltration patterns.

This antibody is part of a broader selection of immune cell marker antibodies designed to support studies of T cell biology, immune infiltration, and tumor immunology, including application-specific CD8A antibody reagents for IHC, FACS, WB, and IF.

Application Notes

The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the CD8A Antibody / Tumor Infiltrating Lymphocyte Marker Antibody to be titered up or down for optimal performance.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Recombinant full-length human CD8a protein was used as immunogen for this recombinant CD8 antibody.

Storage

Store the recombinant CD8 antibody (with azide) at 2-8oC. The azide-free format should be aliquoted and stored at -20oC or colder.

Alternate Names

CD8A tumor infiltrating lymphocyte marker antibody, CD8 alpha TIL marker antibody, CD8A tumor immune infiltration antibody, CD8A cancer immune marker antibody, CD8A tumor microenvironment antibody

References (1)